Revascor is a cell therapy commercialized by Mesoblast, with a leading Phase III program in Chronic Heart Failure. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Revascor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Revascor is expected to reach an annual total of $465 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Rexlemestrocel-L is under development for the treatment of acute myocardial infarction, end-stage hypoplastic left heart syndrome, advanced (class II-IV) chronic congestive heart failure due to left ventricular dysfunction and end-stage ischemic heart failure. It is administered as intra-myocardial (intra-cardiac) injection. The therapeutic candidate is based on mesenchymal precursor cell (MPC) technology platform.
Mesoblast is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.
The company reported revenues of (US Dollars) US$10.2 million for the fiscal year ended June 2022 (FY2022), an increase of 37% over FY2021. The operating loss of the company was US$74.1 million in FY2022, compared to an operating loss of US$85.2 million in FY2021. The net loss of the company was US$91.4 million in FY2022, compared to a net loss of US$98.8 million in FY2021. The company reported revenues of US$1.5 million for the first quarter ended September 2022, a decrease of 32.5% over the previous quarter.
For a complete picture of Revascor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.